公开(公告)号：US06391542B1

公开(公告)日：2002-05-21

申请号：US08650093

申请日：1996-05-17

申请人： Kevin P. Anderson ,  Ronnie C. Hanecak ,  Kazuya Hoshiko ,  Chikateru Nozaki ,  Tsukasa Nishihara ,  Hiroshi Nakatake ,  Fukusaburo Hamada ,  Tatsuo Eto ,  Shinichi Furukawa ,  Shoji Furasako ,  Thomas W. Bruice ,  Walter F. Lima

发明人： Kevin P. Anderson ,  Ronnie C. Hanecak ,  Kazuya Hoshiko ,  Chikateru Nozaki ,  Tsukasa Nishihara ,  Hiroshi Nakatake ,  Fukusaburo Hamada ,  Tatsuo Eto ,  Shinichi Furukawa ,  Shoji Furasako ,  Thomas W. Bruice ,  Walter F. Lima

IPC分类号： C12Q168

CPC分类号： C12N15/1131 ,  C07H21/00 ,  C07K14/005 ,  C12N2310/315 ,  C12N2310/33 ,  C12N2310/3521 ,  C12N2310/3527 ,  C12N2770/24222 ,  C12Q1/707

摘要： Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.

摘要翻译： 提供反义寡核苷酸，其与至少一部分HCV RNA互补并可与其相互杂交，并能够抑制HCV RNA的功能。 可以施用这些寡核苷酸来体内或体外抑制丙型肝炎病毒的活性。 这些化合物可以预防性地或治疗性地用于降低与丙型肝炎病毒相关的疾病的严重性，以及HCV和HCV相关疾病的诊断和检测。 还公开了使用这些化合物的方法。

公开(公告)号：US06284458B1

公开(公告)日：2001-09-04

申请号：US08397220

申请日：1995-03-09

申请人： Kevin P. Anderson ,  Ronnie C. Hanecak ,  Kazuya Hoshiko ,  Chikateru Nozaki ,  Tsukasa Nishihara ,  Hiroshi Nakatake ,  Fukusaburo Hamada ,  Tatsuo Eto ,  Shinichi Furukawa

发明人： Kevin P. Anderson ,  Ronnie C. Hanecak ,  Kazuya Hoshiko ,  Chikateru Nozaki ,  Tsukasa Nishihara ,  Hiroshi Nakatake ,  Fukusaburo Hamada ,  Tatsuo Eto ,  Shinichi Furukawa

IPC分类号： C12Q168

CPC分类号： C12N15/1131 ,  C07H21/00 ,  C07K14/005 ,  C12N2310/315 ,  C12N2310/33 ,  C12N2310/3521 ,  C12N2310/3527 ,  C12N2770/24222 ,  C12Q1/707

摘要： Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.

公开(公告)号：US06423489B1

公开(公告)日：2002-07-23

申请号：US08452841

申请日：1995-05-30

申请人： Kevin P. Anderson ,  Ronnie C. Hanecak ,  Kazuya Hoshiko ,  Chikateru Nozaki ,  Tsukasa Nishihara ,  Hiroshi Nakatake ,  Fukusaburo Hamada ,  Tatsuo Eto ,  Shinichi Furukawa ,  Shoji Furusako ,  Thomas W. Bruice ,  Walter F. Lima

发明人： Kevin P. Anderson ,  Ronnie C. Hanecak ,  Kazuya Hoshiko ,  Chikateru Nozaki ,  Tsukasa Nishihara ,  Hiroshi Nakatake ,  Fukusaburo Hamada ,  Tatsuo Eto ,  Shinichi Furukawa ,  Shoji Furusako ,  Thomas W. Bruice ,  Walter F. Lima

IPC分类号： C12Q168

CPC分类号： C12N15/1131 ,  C07H21/00 ,  C07K14/005 ,  C12N2310/315 ,  C12N2310/33 ,  C12N2310/3521 ,  C12N2310/3527 ,  C12N2770/24222 ,  C12Q1/707

摘要： Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.